Alliance Revenue (Tables)

3 Months Ended

Mar. 31, 2018

Schedule of accompanying statements of operations and comprehensive loss


	Three months ended
	March 31,
(In thousands)	2018		2017
GSK collaboration (1)	$	142	$	371
Vivelix collaboration (2)		56		—
Other (3)		57		7
Total Alliance revenue	$	255	$	378

(1)

For the three months ended March 31, 2018, revenue recognized primarily relates to the amortization of the deferred up-front payment received at inception of the GSK Agreement, as more fully described in Note 9. For the three months ended March 31, 2017, revenue recognized includes $0.3 million related to the amortization of the deferred up-front payment and $0.1 million related to additional research services provided in connection with the arrangement.

(2)

For the three months ended March 31, 2018, revenue recognized relates to services provided under the research program provided for under the Vivelix Agreement, as more fully described in Note 9.

(3)

For each of the three months ended March 31, 2018 and 2017, revenue recognized relates to collaborations which are not material to our current operations nor expected to be material in the future, including reimbursements by licensees of costs associated with patent maintenance.

Schedule of changes in the Company’s contract assets and liabilities


	Three months ended March 31, 2018
(In thousands)	Beginning		Additions		Deductions		Ending
Contract assets	$	—	$	—	$	—	$	—
Contract liabilities:
Deferred revenue	$	566	$	—	$	(190)	$	376


	Three months ended March 31, 2017
(In thousands)	Beginning		Additions		Deductions		Ending
Contract assets	$	—	$	—	$	—	$	—
Contract liabilities:
Deferred revenue	$	1,263	$	—	$	(278)	$	985